Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Dispatch

Chronic Pulmonary Disease Caused by Tsukamurella toyonakaense

Tomoki Kuge, Kiyoharu FukushimaComments to Author , Yuki Matsumoto, Haruko Saito, Yuko Abe, Eri Akiba, Kako Haduki, Tadayoshi Nitta, Akira Kawano, Michio Tanaka, Yumi Hattori, Takahiro Kawasaki, Takanori Matsuki, Takayuki Shiroyama, Daisuke Motooka, Kazuyuki Tsujino, Keisuke Miki, Masahide Mori, Seigo Kitada, Shota Nakamura, Tetsuya Iida, Atsushi Kumanogoh, and Hiroshi Kida
Author affiliations: Osaka University, Osaka, Japan (T. Kuge, K. Fukushima, Y. Matsumoto, Y. Abe, M. Tanaka, Y. Hattori, T. Shiroyama, D. Motooka, S. Nakamura, T. Iida, A. Kumanogoh); Toneyama Medical Center, Osaka (K. Fukushima, H. Saito, E. Akiba, K. Haduki, T. Nitta, A. Kawano, T. Kawasaki, T. Matsuki, K. Tsujino, K. Miki, M. Mori, H. Kida); Kitada Respiratory Clinic, Osaka (S. Kitada)

Main Article

Table 2

Characteristics of 10 patients who had Tukamurella pulmonary disease*

Report author, year Patient, age, y/sex/country Medical history Signs/symptoms Imaging findings Initial diagnosis of infection Identified pathogen/ diagnostic method Initial treatment; clinical response Subsequent treatment
Tsukamura et al., 1982 50/M/Japan None Fever, cough for 1 week Cavity, pleural effusion Mycobacterium tuberculosis Gemmatimonas aurantiaca/biochemical tests INH, RFP, STM for 2 months; improved NA
Alcaide et al., 2004 55/M/USA Cutaneous T-cell lymphoma, AIDS Fever, cough, fatigue, for 2 weeks Cavity, bilateral infiltrates Mycobacterium Tsukamurella sp./biochemical tests CPF, RFB for 12 weeks; cured NA
Perez et al., 2008 71/M/USA None Fever, cough, hemoptysis for 3 months Cavitary mass Mycobacterium T. pulmonis/biochemical tests RFB, LVF for 6 months; cured NA
Maalouf et al., 2009 76/M/USA Non-Hodgkin lymphoma, COPD Fever, cough, fatigue, for 4 days Bilateral infiltrates Streptococcus pneumoniae T. pulmonis/biochemical tests, 16S rRNA sequencing MEP, VCM for 10 days; symptoms decreased CPFX and RFP for 4 months; improved
Menard et al., 2009 54/M/France Lung transplant 4 years ago Cough for 10 days NR Gram-positive bacilli T. tyrosinosolvens/16S rRNA and hsp65 sequencing IPM, TOB; symptoms decreased NA
Inchingolo et al., 2010 76/F/Italy COPD, diabetes mellitus, bilateral glaucoma. Altered state of consciousness, dyspnea for 2 days Ground-glass opacities, infiltrates, pleural effusion Staphylococcus epidermidis T. pulmonis/16S rRNA sequencing AMP/CVA, AZM→AMP/CVA, CPF; symptoms decreased CPFX for 10 days, cured
Mehta et al., 2011 79/M/USA Coronary artery disease, atrial fibrillation Fever, cough, bloody tinge for 10 days Infiltrate Mycobacterium sp. Tsukamurella sp./HPLC First-line CTR, AZM/ NE; second-line INH, RFP, EMB, PZA, AZM/NE CPFX and AZM, improved
Chen et al., 2016 75/M/Taiwan Diabetes mellitus, COPD Fever, cough, general malaise for 1 week Infiltrate Nocardia sp. T. tyrosinosolvens/biochemical tests, 16S rRNA sequencing First- line CTR, AZM for 1 week, treatment failure; second-line IPM for 3 weeks, STM for 4 weeks; condition improved INH; EB; and RFP for 12 months, improved
Yang et al., 2017 24/F/Unknown None Fever, cough, hemoptysis Cavity, infiltrated mass Mycobacterium tuberculosis T. paurametabora/16S rRNA sequencing First-line standard antituberculosis treatment, symptoms improved; second-line intensive antituberculosis therapy for 20 days; treatment failure LNZ for 3 weeks, improved
This study 81/F/Japan NTM-PD Cough, hemoptysis for years Bilateral centrilobular nodules, bronchiectasis Rapidly growing mycobacterium Tsukamurella sp. nov./WGS ERY 20 years, slow progress NA

*Full reference lists for Tukamurella pulmonary disease reported cases are shown in Appendix . AMP/CVA, amoxicillin/clavulanate; AZM, azithromycin; CPF, ciprofloxacin; CTR, ceftriaxone; EMB; ethambutol; ERY, erythromycin; HPLC, high-performance liquid chromatography; hsp, heat-shock protein; INH, isoniazid; IPM, imipenem; LNZ, linezolid; LVF, levofloxacin; MEP, meropenem; NA, not available; NE, not evaluated; NTM-TB, nontuberculous mycobacteria tuberculosis; NR, not reported; PZA, pyrazinamide; RFB, rifabutin; STM, streptomycin; SMX/TMP, sulfamethoxazole/trimethoprim; TOB, tobramycin; VCM, vancomycin.; WGS, whole-genome sequencing.

Main Article

Page created: May 03, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external